Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 23000581)

1.

Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.

Liu HY, Chung CY, Yang WC, Liang CL, Wang CY, Chang CY, Chang CL.

J Vet Sci. 2012 Sep;13(3):245-52.

2.

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS.

J Am Soc Nephrol. 2007 Apr;18(4):1227-38. Epub 2007 Mar 14.

3.
4.

Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.

Patel V, Joharapurkar A, Gandhi T, Patel K, Dhanesha N, Kshirsagar S, Dhote V, Detroja J, Bahekar R, Jain M.

J Diabetes. 2013 Jun;5(2):163-71. doi: 10.1111/j.1753-0407.2012.00227.x.

PMID:
22830490
5.

Toll-like receptor 2- and MyD88-dependent phosphatidylinositol 3-kinase and Rac1 activation facilitates the phagocytosis of Listeria monocytogenes by murine macrophages.

Shen Y, Kawamura I, Nomura T, Tsuchiya K, Hara H, Dewamitta SR, Sakai S, Qu H, Daim S, Yamamoto T, Mitsuyama M.

Infect Immun. 2010 Jun;78(6):2857-67. doi: 10.1128/IAI.01138-09. Epub 2010 Apr 5.

6.

Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus.

Sano H, Terasaki J, Mishiba Y, Imagawa A, Hanafusa T.

Biochem Biophys Res Commun. 2011 Jan 21;404(3):756-61. doi: 10.1016/j.bbrc.2010.12.020. Epub 2010 Dec 7.

PMID:
21144822
7.

Down-regulation of zinc transporter 8 in the pancreas of db/db mice is rescued by Exendin-4 administration.

Liu BY, Jiang Y, Lu Z, Li S, Lu D, Chen B.

Mol Med Rep. 2011 Jan-Feb;4(1):47-52. doi: 10.3892/mmr.2010.392. Epub 2010 Nov 1.

PMID:
21461562
8.

Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.

Simonsen L, Pilgaard S, Orskov C, Hartmann B, Holst JJ, Deacon CF.

Diabetes Obes Metab. 2009 Sep;11(9):884-90. doi: 10.1111/j.1463-1326.2009.01066.x. Epub 2009 Jun 5.

PMID:
19508463
9.

A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.

Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, Lee S, Lee KC.

J Control Release. 2009 Feb 10;133(3):172-7. doi: 10.1016/j.jconrel.2008.09.091. Epub 2008 Oct 21.

PMID:
18977255
10.

Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation.

Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, Hedrick CC.

J Biol Chem. 2006 Jul 28;281(30):21216-24. Epub 2006 May 24.

11.

Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.

Chae SY, Jin CH, Shin JH, Son S, Kim TH, Lee S, Youn YS, Byun Y, Lee MS, Lee KC.

J Control Release. 2010 Mar 3;142(2):206-13. doi: 10.1016/j.jconrel.2009.10.025. Epub 2009 Nov 10.

PMID:
19900495
12.

Role of macrophage scavenger receptors in response to Listeria monocytogenes infection in mice.

Ishiguro T, Naito M, Yamamoto T, Hasegawa G, Gejyo F, Mitsuyama M, Suzuki H, Kodama T.

Am J Pathol. 2001 Jan;158(1):179-88.

13.

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.

Wang Q, Brubaker PL.

Diabetologia. 2002 Sep;45(9):1263-73. Epub 2002 Apr 26.

PMID:
12242459
14.

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.

Dhanesha N, Joharapurkar A, Shah G, Dhote V, Kshirsagar S, Bahekar R, Jain M.

Pharmacol Rep. 2012;64(1):140-9.

15.

Effect of Chinese prescription Kangen-karyu on lipid metabolism in type 2 diabetic db/db mice.

Yamabe N, Kim HY, Kang KS, Zhao Q, Matsumoto K, Yokozawa T.

J Ethnopharmacol. 2010 Jun 16;129(3):299-305. doi: 10.1016/j.jep.2010.03.032. Epub 2010 Apr 2.

PMID:
20363309
16.

Anti-diabetic atherosclerosis effect of Prunella vulgaris in db/db mice with type 2 diabetes.

Hwang SM, Kim JS, Lee YJ, Yoon JJ, Lee SM, Kang DG, Lee HS.

Am J Chin Med. 2012;40(5):937-51. doi: 10.1142/S0192415X12500693.

PMID:
22928826
17.

Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.

Kong JH, Oh EJ, Chae SY, Lee KC, Hahn SK.

Biomaterials. 2010 May;31(14):4121-8. doi: 10.1016/j.biomaterials.2010.01.091. Epub 2010 Feb 10.

PMID:
20149450
18.

Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.

Gezginci-Oktayoglu S, Sacan O, Yanardag R, Karatug A, Bolkent S.

Peptides. 2011 Feb;32(2):223-31. doi: 10.1016/j.peptides.2010.10.025. Epub 2010 Nov 3.

PMID:
21055431
19.

Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice.

Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, Fukami A, Hamada Y, Inagaki N, Seino Y, Drucker DJ, Oiso Y, Nakamura J.

Diabetes. 2011 Sep;60(9):2397-406. doi: 10.2337/db10-1462. Epub 2011 Aug 1.

20.

Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.

Xue S, Wasserfall C, Parker M, McGrail S, McGrail K, Campbell-Thompson M, Schatz DA, Atkinson MA, Haller MJ.

J Diabetes Complications. 2010 May-Jun;24(3):163-7. doi: 10.1016/j.jdiacomp.2008.12.004. Epub 2009 Feb 13.

PMID:
19217320
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk